688253.SHG Innovita Biological Technology Co. Ltd. A
- Market cap
- CNY 6.72B
- P/E
- 116.0x
- P/B
- 3.16x
- ROE
- 3.1%
- Dividend yield
- 1.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688253.SHG undervalued?
Graham numberThe Graham number of Innovita Biological Technology Co. Ltd. A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innovita Biological Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Innovita Biological Technology Co. Ltd. A yet.
Innovita Biological Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in research and development, production and sales of POCT rapid diagnostic products. It offers Covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test and TORCH test, neurological testing and hepatitis test, as well as tropical disease test such as neurological testing. The company was founded in 2006 and is based in Beijing, China.
Full company profileInnovita Biological Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Innovita Biological Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 1.04B | 327M | 447M | 478M | 621M | 422M | 281M |
| Gross Profit | 927M | 251M | 273M | 363M | 498M | 330M | 200M |
| Operating Income | 711M | 146M | 119M | 216M | 249M | 129M | 28.3M |
| EBITDA | - | - | 184M | 224M | 298M | 186M | 68.2M |
| Net Income | 571M | 120M | 151M | 174M | 247M | 144M | 62.2M |
| EPS | 5.60 | 1.18 | 1.11 | 1.28 | 1.81 | 1.05 | 0.45 |
| Balance Sheet | |||||||
| Total Assets | 782M | 798M | 1.94B | 2.07B | 2.21B | 2.28B | 2.13B |
| Total Liabilities | 114M | 59.7M | 253M | 224M | 219M | 223M | 97.7M |
| Shareholders' Equity | 668M | 738M | 1.69B | 1.84B | 1.99B | 2.05B | 2.03B |
| Cash & Short-term Investments | 482M | 480M | 389M | 166M | 308M | 567M | 362M |
| Cash Flow | |||||||
| Operating Cash Flow | 640M | 106M | 126M | 260M | 305M | 193M | - |
| Capital Expenditure | 76.7M | 63.7M | 57.7M | 17.0M | 36.2M | 31.1M | 7.44M |
| Free Cash Flow | 563M | 42.5M | 68.7M | 243M | 269M | 162M | -132M |
| Ratios | |||||||
| ROE | 85.6% | 16.3% | 8.9% | 9.4% | 12.4% | 7.0% | 3.1% |
| ROA | 73.1% | 15.1% | 7.8% | 8.4% | 11.2% | 6.3% | 2.9% |
| Net Profit Margin | 55.1% | 36.8% | 33.7% | 36.4% | 39.7% | 34.2% | 22.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Innovita Biological Technology Co. Ltd. A dividends
- Dividend yield
- 1.12%
- Forward dividend
- 0.45 CNY
- Payout ratio
- 52.1%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 75.2M | 0.55 | 52.1% |
| 2024 | CNY 54.4M | 0.40 | 22.0% |
| 2023 | CNY 22.6M | 0.17 | 13.0% |
| 2022 | CNY 217K | 0.00 | 0.1% |
| 2021 | CNY 50.1M | 0.49 | 41.6% |
| 2020 | CNY 100M | 0.98 | 17.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Innovita Biological Technology Co. Ltd. A
- Insiders 53.81%
- Institutions 1.98%
- Public & others 44.21%
- Shares outstanding 138M
- Free float 125M
Innovita Biological Technology Co. Ltd. A company profile
- Company name
- Innovita Biological Technology Co. Ltd. A
- Ticker
- 688253.SHG
- ISIN
- CNE100005Q14
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 571
- Fiscal year end
- December
- Address
- 1st and 2nd floors, Beijing, China, 100070
- Phone
- 86 10 8368 1277
- Website
- innovita.com.cn
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in research and development, production and sales of POCT rapid diagnostic products. It offers Covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test and TORCH test, neurological testing and hepatitis test, as well as tropical disease test such as neurological testing. The company was founded in 2006 and is based in Beijing, China.
Innovita Biological Technology Co. Ltd. A management
5- Ms. Xiujie ZhangGM & Director · born 1971
- Ms. Xiujuan ZhaoFinancial Director & Director · born 1974
- Mr. Xiaogang ZhangDeputy GM & Director · born 1964
- Mr. Fukang ChenBoard Secretary · born 1984
- Yingsheng ZhaoAccounting Supervisor